Urologix Analysis

Urologix Pink Sheet Analysis Notes

The company recorded a loss per share of 0.22. Urologix had not issued any dividends in recent years. Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia in the United States. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota. UROLOGIX operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 61 people.The quote for Urologix is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more information please call Bryon Merade at 763 475 1400 or visit https://www.urologix.com.

Urologix Investment Alerts

Urologix Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 82.91 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Urologix's market, we take the total number of its shares issued and multiply it by Urologix's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Urologix Profitablity

The company has Profit Margin (PM) of (0.39) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.07) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.07.

Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Urologix prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Urologix shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Urologix. By using and applying Urologix Pink Sheet analysis, traders can create a robust methodology for identifying Urologix entry and exit points for their positions.

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Urologix information on this page should be used as a complementary analysis to other Urologix's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

If you are still planning to invest in Urologix check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Urologix's history and understand the potential risks before investing.